No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
AZN241227P68000
- 2.01
- -0.64-24.15%
15min DelayClose Dec 23 16:00 ET
2.01High2.01Low
2.01Open2.65Pre Close2 Volume37 Open Interest68.00Strike Price402.00Turnover18.75%IV0.96%PremiumDec 27, 2024Expiry Date1.37Intrinsic Value100Multiplier4DDays to Expiry0.64Extrinsic Value100Contract SizeAmericanOptions Type-0.8529Delta0.1906Gamma46.11Leverage Ratio-0.0323Theta-0.0044Rho-39.33Eff Leverage0.0156Vega
Intraday
- 5D
- Daily
News
Express News | US FDA: Revoked Emergency Use Authorization for AstraZeneca's Evusheld as of Dec 13 - Website
London Shares Rise; UK Economy Flatlines
Unusual Options Activity: COIN, AZN and Others Attract Market Bets, COIN V/OI Ratio Reaches 120.0
EST Dec 23rd Morning Delivery - In the last two hours of trading, 5 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
AstraZeneca's Blockbuster Drug Tagrisso Wins EU Nod for Non-small Cell Lung Cancer
AstraZeneca Obtains EU Approval for Tagrisso in Non-small Cell Lung Cancer Treatment
AstraZeneca's Tagrisso Gains EU Approval for Unresectable EGFR-Mutated Lung Cancer